Klygefa (gefurulimab-gaks): FDA approval, pivotal trial and safety

Approved
Type
Therapeutic biologic · Injection
FDA-approved use
To treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravisWording from FDA's list of novel approvals.
FDA review
Standard review
Company
Alexion
Application
BLA 761488

At a glance

Klygefa (gefurulimab-gaks) is a complement C5 inhibitor approved for anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. In the phase 3 PREVAIL trial, the MG-ADL score at week 26 improved by 1.6 points more than with placebo (95% CI, -2.4 to -0.8; P < .001). Adverse event rates were similar to placebo, and no meningococcal infections were reported.

What it is and how it works

Gefurulimab is a nanobody that binds complement component 5 (C5) and blocks its activation. Complement activation is a key disease mechanism in AChR antibody-positive generalized myasthenia gravis. Other C5 inhibitors are given by infusion. Gefurulimab is small enough for subcutaneous self-injection once weekly, by autoinjector or prefilled syringe. A phase 1 study in healthy adults found the two devices had comparable exposure.

Pivotal trials

PREVAIL NCT05556096

Design
Phase 3, randomized, double-blind, placebo-controlled trial at 113 sites in 20 countries, with a 26-week controlled treatment period.
Patients
260 adults with AChR antibody-positive generalized myasthenia gravis (MGFA class II to IV, MG-ADL total score of 5 or higher): 131 on gefurulimab and 129 on placebo. Mean age was 52.8 years and 60.4% were female. 249 completed the 26 weeks.
Compared with
Placebo, given by once-weekly subcutaneous self-injection.
Primary endpoint
Change from baseline in MG-ADL total score at week 26.

Result

Least-squares mean change was -4.2 with gefurulimab vs -2.6 with placebo. The treatment difference was -1.6 (95% CI, -2.4 to -0.8; P < .001). Improvement appeared within 1 week and was sustained through week 26.

Other results
The key secondary end point was change in QMG total score at week 26: -4.5 vs -2.4 (difference, -2.1; 95% CI, -3.1 to -1.1; P < .001). Improvement appeared within 4 weeks. All primary and secondary end points were met.
Safety in the trial
Adverse event incidence was similar between groups. Common events with gefurulimab were injection site reactions, headache, back pain, and nasopharyngitis. No meningococcal infections were reported.

Source: Gwathmey KG, et al. Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial. JAMA Neurol. 2026;83:841-850.

EvidencePulse™

Ask about Klygefa

The question that opens in EvidencePulse

How does Klygefa (gefurulimab-gaks) compare with the alternatives (Pyridostigmine, Corticosteroids and other immunosuppressants (such as azathioprine, mycophenola…, Eculizumab) for anti-acetylcholine receptor antibody-positive generalized myasthenia gravis? Summarize head-to-head and indirect evidence, efficacy, safety and where each fits, with citations.

Ask in EvidencePulseFree to try, more with 2MM+.

Deep research is a core feature of 2MM Max.

Safety signals

The label carries no boxed warning. In PREVAIL, adverse event rates were similar between gefurulimab and placebo. The most common events with gefurulimab were injection site reactions, headache, back pain, and nasopharyngitis. No meningococcal infections were reported in the trial. Because the drug blocks C5, clinicians should still consider infection risk and check the label for warnings and vaccination advice. In the phase 1 device study, most events were mild and none led to discontinuation.

What it competes with

Generalized myasthenia gravis is usually treated with cholinesterase inhibitors plus corticosteroids and other immunosuppressants. Targeted biologics are added when disease remains active.

  • PyridostigmineCholinesterase inhibitor used for symptom relief; does not alter the underlying immune process.
  • Corticosteroids and other immunosuppressants (such as azathioprine, mycophenola…Standard long-term immune suppression; corticosteroids carry cumulative toxicity, and the other agents act slowly.
  • EculizumabIntravenous C5 inhibitor approved for AChR antibody-positive disease; requires infusions and meningococcal precautions.
  • RavulizumabLong-acting intravenous C5 inhibitor with less frequent infusions; also requires meningococcal precautions.
  • EfgartigimodNeonatal Fc receptor blocker that lowers IgG antibodies, a different mechanism from complement inhibition.

Bottom line for clinicians

Klygefa is an option for adults with AChR antibody-positive generalized myasthenia gravis who may want a self-administered complement inhibitor. The benefit over placebo was significant on both the MG-ADL and QMG scales over 26 weeks. Weigh infection risk from C5 blockade, the lack of head-to-head data against other targeted therapies, and the limited trial length.

Our coverage

We have not covered this drug yet.

Sources

  1. Full prescribing information (FDA)
  2. FDA list of novel approvals
  3. Gwathmey KG, et al. Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial. JAMA Neurol. 2026;83:841-850.
  4. ClinicalTrials.gov NCT05556096
  5. McEneny A, et al. Phase 1 Study Evaluating Gefurulimab Pharmacokinetics and Safety Following Delivery Via Autoinjector or Prefilled Syringe With Needle Safety Device in Healthy Adults. Clin Ther. 2026;48:1030-1036.

Dosing, contraindications and full warnings are in the prescribing information.

New FDA approvals in your inbox

The free 2 Minute Medicine Daily Brief: new approvals, landmark trials and the day's top studies, written by physicians.

Your subscription opens securely in a new tab.

Last updated November 17, 2026 by 2 Minute Medicine.

For healthcare professionals. A summary of public FDA documents and published trials, not medical advice. Check the full prescribing information before prescribing.